Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 59


Natural underlying mtDNA heteroplasmy as a potential source of intra-person hiPSC variability.

Perales-Clemente E, Cook AN, Evans JM, Roellinger S, Secreto F, Emmanuele V, Oglesbee D, Mootha VK, Hirano M, Schon EA, Terzic A, Nelson TJ.

EMBO J. 2016 Sep 15;35(18):1979-90. doi: 10.15252/embj.201694892.


Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells.

Aho JM, Dietz AB, Radel DJ, Butler GW, Thomas M, Nelson TJ, Carlsen BT, Cassivi SD, Resch ZT, Faubion WA, Wigle DA.

Stem Cells Transl Med. 2016 Oct;5(10):1375-1379.


Mapping transcriptome profiles of in vitro iPSC-derived cardiac differentiation to in utero heart development.

Li X, Campbell KA, Biendarra SM, Terzic A, Nelson TJ.

Genom Data. 2015 Dec 30;7:129-30. doi: 10.1016/j.gdata.2015.12.022.


Hypoplastic left heart syndrome: What's next?

Burkhart HM, Thompson JL, Nelson TJ.

J Thorac Cardiovasc Surg. 2016 Apr;151(4):909-10. doi: 10.1016/j.jtcvs.2015.12.032. No abstract available.


Modeling structural and functional deficiencies of RBM20 familial dilated cardiomyopathy using human induced pluripotent stem cells.

Wyles SP, Li X, Hrstka SC, Reyes S, Oommen S, Beraldi R, Edwards J, Terzic A, Olson TM, Nelson TJ.

Hum Mol Genet. 2016 Jan 15;25(2):254-65. doi: 10.1093/hmg/ddv468.


Ebstein anomaly review: what's now, what's next?

Dearani JA, Mora BN, Nelson TJ, Haile DT, O'Leary PW.

Expert Rev Cardiovasc Ther. 2015 Oct;13(10):1101-9. doi: 10.1586/14779072.2015.1087849. Review.


Nos3-/- iPSCs model concordant signatures of in utero cardiac pathogenesis.

Campbell KA, Li X, Biendarra SM, Terzic A, Nelson TJ.

J Mol Cell Cardiol. 2015 Oct;87:228-36. doi: 10.1016/j.yjmcc.2015.08.021.


Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis in a patient with hypoplastic left heart syndrome.

Theis JL, Hrstka SC, Evans JM, O'Byrne MM, de Andrade M, O'Leary PW, Nelson TJ, Olson TM.

Hum Genet. 2015 Sep;134(9):1003-11. doi: 10.1007/s00439-015-1582-1.


Regenerative Therapy Prevents Heart Failure Progression in Dyssynchronous Nonischemic Narrow QRS Cardiomyopathy.

Yamada S, Arrell DK, Martinez-Fernandez A, Behfar A, Kane GC, Perez-Terzic CM, Crespo-Diaz RJ, McDonald RJ, Wyles SP, Zlatkovic-Lindor J, Nelson TJ, Terzic A.

J Am Heart Assoc. 2015 May 11;4(5). pii: e001614. doi: 10.1161/JAHA.114.001614.


Human umbilical cord blood-derived mononuclear cells improve murine ventricular function upon intramyocardial delivery in right ventricular chronic pressure overload.

Oommen S, Yamada S, Cantero Peral S, Campbell KA, Bruinsma ES, Terzic A, Nelson TJ.

Stem Cell Res Ther. 2015 Mar 26;6:50. doi: 10.1186/s13287-015-0044-y.


Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system.

Cantero Peral S, Burkhart HM, Oommen S, Yamada S, Nyberg SL, Li X, O'Leary PW, Terzic A, Cannon BC, Nelson TJ; Wanek Program Porcine Pipeline Group..

Stem Cells Transl Med. 2015 Feb;4(2):195-206. doi: 10.5966/sctm.2014-0195.


Regenerative therapy for hypoplastic left heart syndrome: first report of intraoperative intramyocardial injection of autologous umbilical-cord blood-derived cells.

Burkhart HM, Qureshi MY, Peral SC, O'Leary PW, Olson TM, Cetta F, Nelson TJ; Wanek Program Clinical Pipeline Group..

J Thorac Cardiovasc Surg. 2015 Mar;149(3):e35-7. doi: 10.1016/j.jtcvs.2014.10.093. No abstract available.


Stem cells: the pursuit of genomic stability.

Wyles SP, Brandt EB, Nelson TJ.

Int J Mol Sci. 2014 Nov 14;15(11):20948-67. doi: 10.3390/ijms151120948. Review.


Utilization of stem cells to treat congenital heart disease: hype and hope.

Peral SC, Burkhart HM, Nelson TJ.

Curr Opin Pediatr. 2014 Oct;26(5):553-60. doi: 10.1097/MOP.0000000000000138. Review.


iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes.

Martinez-Fernandez A, Nelson TJ, Reyes S, Alekseev AE, Secreto F, Perez-Terzic C, Beraldi R, Sung HK, Nagy A, Terzic A.

Circ Cardiovasc Genet. 2014 Oct;7(5):667-76. doi: 10.1161/CIRCGENETICS.113.000298.


Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy.

Wyles SP, Yamada S, Oommen S, Maleszewski JJ, Beraldi R, Martinez-Fernandez A, Terzic A, Nelson TJ.

Stem Cells Dev. 2014 Oct 1;23(19):2274-82. doi: 10.1089/scd.2014.0259.


The inferred cardiogenic gene regulatory network in the mammalian heart.

Bazil JN, Stamm KD, Li X, Thiagarajan R, Nelson TJ, Tomita-Mitchell A, Beard DA.

PLoS One. 2014 Jun 27;9(6):e100842. doi: 10.1371/journal.pone.0100842.


Transcriptional atlas of cardiogenesis maps congenital heart disease interactome.

Li X, Martinez-Fernandez A, Hartjes KA, Kocher JP, Olson TM, Terzic A, Nelson TJ.

Physiol Genomics. 2014 Jul 1;46(13):482-95. doi: 10.1152/physiolgenomics.00015.2014.


Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity.

Hartjes KA, Li X, Martinez-Fernandez A, Roemmich AJ, Larsen BT, Terzic A, Nelson TJ.

Stem Cells. 2014 Sep;32(9):2350-9. doi: 10.1002/stem.1734.

Items per page

Supplemental Content

Loading ...
Support Center